Missoula, MT, June 5, 2023 – Inimmune, a leading biotech company focused on the development of novel vaccine adjuvants, immunotherapies and delivery systems, announced today that its Chief Scientific and Strategy Officer, Jay Evans, Ph.D., will provide an update on company programs and clinical trials on May 5th at BIO International Convention in Boston, MA (https://www.bio.org/events/bio-international-convention).
Inimmune has accrued a deep pipeline of innovative vaccines, adjuvants, and immunotherapy assets poised for rapid development and clinical advancement. Two of these assets are entering Phase I human clinical trials in mid and late 2023, targeting seasonal allergic rhinitis and immuno-oncology. This will be followed by additional clinical trials in 2024 for vaccines targeting opioid addition and infectious diseases.
“This is a transformative year for Inimmune as we make the transition from a pre-clinical to clinical stage biotech company” said Alan Joslyn, CEO of Inimmune. “Inimmune scientists are advancing novel vaccines and immunotherapies in areas of critical importance to global health.” BIO is the world largest advocacy association representing companies, academic and private research institutions, and state/national biotechnology organizations across the world. Each year these organizations come together at the BIO International Convention for networking, partnering, and education. Inimmune is a member of BIO and actively participates at the Convention through partnering meetings and company updates.
Inimmune Corp. (Missoula, MT) is a privately held biotechnology company focused on the discovery and development of innovative immunotherapeutics, vaccine adjuvants and vaccines. Inimmune is harnessing the human immune system to create safe and effective treatments for allergy, infectious disease, autoimmunity and cancer. Their laboratories and offices are housed in the Montana Technology Enterprise Center (MonTEC) in Missoula.
For more information on Inimmune’s research and development of novel vaccine adjuvants and delivery
systems, please visit www.inimmune.com.